



Smruthi Organics Limited

Date: 05th August, 2023

To
Corporate Relation Department
BSE Limited
P. J. Tower, Dalal Street,
Mumbai – 400 001.

To
Listing Department
Metropolitan Stock Exchange of India Ltd
Building A, Unit 205A, 2nd Floor,
Piramal Agastya Corporate Park,
L.B.S Road, Kurla West, Mumbai – 400070

Scrip Code: 540686

Subject: Outcome of Board meeting of the Company held today i.e. 05th August 2023.

Dear Sir/ Madam.

Kindly note that the Board of Directors of the Company has, in its meeting held today i.e. on Saturday, 05th August, 2023 ("said meeting"), considered and approved the Unaudited Financial Results of the Company for the first quarter ended 30th June, 2023.

Further, pursuant to the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: - (i) the Unaudited Financial Results; and (ii) Limited Review Report dated 05th August, 2023, issued by the Statutory Auditors of the Company w.r.t. the Unaudited Financial Results and taken on record by the Board of Directors of the Company.

Necessary arrangements have been made for publishing the Unaudited Financial results in the newspapers, in the prescribed formats of SEBI Listing Regulations.

The meeting concluded at 11:45 p.m

Kindly take on record the above information and acknowledge.

For Smruthi Organics Limited

Urvashi D. Khosla
Company Secretary & Compliance Officer

Smruthi Organics Limited

Registered & Corporate Office.: 165-A, Balaji Bhavan, 1st Floor, Railway Lines, Solapur-413001 (Maharashtra)
CIN :- L24119PN1989PLC052562

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED June 30, 2023



Rs.in lakhs

Sr.No.	Particulars	Quarter Ended			Year ended
		30/06/2023	31/03/2023	30/06/2022	31/03/2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from operations				
	a) Revenue from operations (Net)	3491.19	3677.66	2907.28	14104.09
	b) Other income	1.09	5.26	3.10	10.74
	Total Revenue from operations & other Income (a+b)	3492.28	3682.92	2910.38	14114.83
2	Expenses				
	a) Cost of materials consumed	2024.18	2504.83	2192.84	9569.33
	b) Purchases of Traded Goods	4.79	1.36	7.43	19.88
	c) Changes in inventories of finished goods & work-in-progress	(6.10)	(138.34)	(356.50)	(441.50)
	d) Employee benefit expenses	397.07	473.03	362.23	1582.46
	e) Finance Costs	32.50	25.03	11.93	82.25
	f) Depreciation and amortisation expenses	123.85	123.87	111.49	457.18
	g) Other expenses	609.44	612.36	529.81	2395.86
	TOTAL Expenses (a+b+c+d+e+f+g)	3185.73	3602.14	2859.23	13665.46
3	Profit/(Loss) before exceptional items and tax (1-2)	306.55	80.78	51.15	449.37
4	Exceptional items	-	-	-	-
5	Profit/ (loss) before tax (3 - 4)	306.55	80.78	51.15	449.37
6	Tax expense				
	a) Current Income Tax	88.55	55.10	22.14	164.32
	b) Other income Tax	-	(20.01)	-	(18.39)
	c) Defered Tax (Asset) / Liability	(11.34)	(23.36)	(1.25)	(109.65)
	Total Tax Expenses (a+b+c)	77.21	11.73	20.89	36.28
7	Net Profit/(Loss) for the period (5 - 6)	229.34	69.05	30.25	413.09
8	Other Comprehensive Income				
	i) Items that will not be reclassified to profit or loss	-	69.40	-	37.54
	(ii) Income tax relating to Items that will not be reclassified to profit or loss.	-	(15.70)	-	(7.68)
	(iii) Items that will be reclassified to profit or loss	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	53.70	-	29.86
9	Total comprehensive income (7 + 8)	229.34	122.75	30.25	442.95
10	Paid-up equity share capital (Face value of Rs.10/- each)	1144.63	1144.63	1144.63	1144.63
11	Earnings per equity share in Rs. (not annualised)				
	a) Basic	2.00	1.07	0.26	3.87
	b) Diluted	2.00	1.07	0.26	3.87

Notes:

- 1 The Operations of the Company constitute Bulk Drugs, Drug Intermediates as a major business segment and Formulations activity as a minor business segment.
- 2 The Statutory Auditor carried out limited review of the unaudited financial results of the Company for the first Quarter ended June 30, 2023
- 3 The above financials were reviewed by the Audit Committee and Approved by the Board of Directors at meeting held on August 5, 2023
- 4 Revenue from Operations (Sales) for the first quarter ended Jun 30, 2023 is net of Goods and Service Tax(GST).
- 5 The results include sale of Rs . 20.86 lakhs and loss of Rs. 18.62 lakhs incurred by the Formulation Division.
- 6 The financial results are prepared in accordance with the Indian Accounting Standards (Ind AS) 108 as prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 7 Previous period's figures have been regrouped / rearranged wherever necessary to conform to the current period's classification.

Place : Solapur
Date : August 5, 2023



(Signature)
E. PURUSHOTHAM
CHAIRMAN & MANAGING DIRECTOR
DIN 00033588



Independent Auditor's Review Report on Unaudited Financial Results for the quarter of SMRUTHI ORGANICS LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of SMRUTHI ORGANICS LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **SMRUTHI ORGANICS LIMITED** ("the Company") for the quarter ended 30th June 2023 ("Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Regulations").
2. This statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to issue a report expressing a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than audit conducted in accordance with Standard on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gokhale & Sathe,

Chartered Accountants

Firm Registration Number: 103264W

CA Kaustubh Deshpande,

Partner

Membership No.:121011

UDIN: 23121011BGXXZE9828

Place: Solapur

Date: August 5, 2023